FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126367595> ?p ?o ?g. }

• W2126367595 abstract "High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by measuring serum regulatory T cell (Treg), serum transforming growth factor-β (TGF-β), interleukin (IL)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose IFN-α 2b regimen. Patients with melanoma received IFN-α 2b administered intravenously (20 MU/m2 each day from day 1 to day 5 for 4 consecutive weeks). Serum Treg levels were measured as whole lymphocytes in CD4+ cells using flow cytometry while TGF-β, IL-10, and autoantibody levels were measured using enzyme-linked immunosorbent assays. Twenty-two patients with melanoma received IFN-α 2b treatment and were evaluated for Treg levels. Before treatment, Treg levels were significantly higher in patients with melanoma when compared with data from 20 healthy subjects (P = 0.001; Mann-Whitney test). Although a trend for reduction of Treg levels following IFN-α 2b treatment was observed (average decrease 0.29% per week), statistical significance was not achieved. Subgroup analyses indicated higher baseline Treg levels for stage III versus IV disease (P = 0.082), early recurrence versus no recurrence (P = 0.017), deceased versus surviving patients (P = 0.021), and preoperative neoadjuvant versus postoperative adjuvant treatment groups (not significant). No significant effects were observed on the levels of TGF-β, IL-10, and autoantibodies in patients with melanoma treated with IFN-α 2b. Patients with melanoma in this study showed increased basal levels of Treg that may be relevant to their disease and its progression. Treg levels shifted in patients with melanoma treated with IFN-α 2b, although no firm conclusions regarding the role of Tregs as a marker of treatment response or outcome can be made at present." @default.
• W2126367595 created "2016-06-24" @default.
• W2126367595 creator A5001257303 @default.
• W2126367595 creator A5007239425 @default.
• W2126367595 creator A5008816822 @default.
• W2126367595 creator A5009799018 @default.
• W2126367595 creator A5011521807 @default.
• W2126367595 creator A5017184993 @default.
• W2126367595 creator A5021763099 @default.
• W2126367595 creator A5029398339 @default.
• W2126367595 creator A5031828012 @default.
• W2126367595 creator A5040267877 @default.
• W2126367595 creator A5048796106 @default.
• W2126367595 creator A5058301344 @default.
• W2126367595 creator A5059941996 @default.
• W2126367595 creator A5071834315 @default.
• W2126367595 creator A5081605398 @default.
• W2126367595 creator A5086592438 @default.
• W2126367595 creator A5089512613 @default.
• W2126367595 date "2010-08-16" @default.
• W2126367595 modified "2023-10-17" @default.
• W2126367595 title "Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment" @default.
• W2126367595 cites W1827509430 @default.
• W2126367595 cites W1828940258 @default.
• W2126367595 cites W1908752382 @default.
• W2126367595 cites W1981218605 @default.
• W2126367595 cites W1990435553 @default.
• W2126367595 cites W2002726823 @default.
• W2126367595 cites W2026426963 @default.
• W2126367595 cites W2042085966 @default.
• W2126367595 cites W2044389879 @default.
• W2126367595 cites W2060555060 @default.
• W2126367595 cites W2063403309 @default.
• W2126367595 cites W2076138163 @default.
• W2126367595 cites W2099289479 @default.
• W2126367595 cites W2101003487 @default.
• W2126367595 cites W2112410464 @default.
• W2126367595 cites W2129814407 @default.
• W2126367595 cites W2130822830 @default.
• W2126367595 cites W2130969574 @default.
• W2126367595 cites W2134210187 @default.
• W2126367595 cites W2136443107 @default.
• W2126367595 cites W2139276825 @default.
• W2126367595 cites W2141785549 @default.
• W2126367595 cites W2142554708 @default.
• W2126367595 cites W2143923888 @default.
• W2126367595 cites W2163890187 @default.
• W2126367595 cites W2418805561 @default.
• W2126367595 cites W2965200460 @default.
• W2126367595 cites W3005352989 @default.
• W2126367595 cites W4256189622 @default.
• W2126367595 doi "https://doi.org/10.1186/1479-5876-8-76" @default.
• W2126367595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2936304" @default.
• W2126367595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20712892" @default.
• W2126367595 hasPublicationYear "2010" @default.
• W2126367595 type Work @default.
• W2126367595 sameAs 2126367595 @default.
• W2126367595 citedByCount "44" @default.
• W2126367595 countsByYear W21263675952012 @default.
• W2126367595 countsByYear W21263675952013 @default.
• W2126367595 countsByYear W21263675952014 @default.
• W2126367595 countsByYear W21263675952015 @default.
• W2126367595 countsByYear W21263675952016 @default.
• W2126367595 countsByYear W21263675952017 @default.
• W2126367595 countsByYear W21263675952019 @default.
• W2126367595 countsByYear W21263675952020 @default.
• W2126367595 countsByYear W21263675952022 @default.
• W2126367595 countsByYear W21263675952023 @default.
• W2126367595 crossrefType "journal-article" @default.
• W2126367595 hasAuthorship W2126367595A5001257303 @default.
• W2126367595 hasAuthorship W2126367595A5007239425 @default.
• W2126367595 hasAuthorship W2126367595A5008816822 @default.
• W2126367595 hasAuthorship W2126367595A5009799018 @default.
• W2126367595 hasAuthorship W2126367595A5011521807 @default.
• W2126367595 hasAuthorship W2126367595A5017184993 @default.
• W2126367595 hasAuthorship W2126367595A5021763099 @default.
• W2126367595 hasAuthorship W2126367595A5029398339 @default.
• W2126367595 hasAuthorship W2126367595A5031828012 @default.
• W2126367595 hasAuthorship W2126367595A5040267877 @default.
• W2126367595 hasAuthorship W2126367595A5048796106 @default.
• W2126367595 hasAuthorship W2126367595A5058301344 @default.
• W2126367595 hasAuthorship W2126367595A5059941996 @default.
• W2126367595 hasAuthorship W2126367595A5071834315 @default.
• W2126367595 hasAuthorship W2126367595A5081605398 @default.
• W2126367595 hasAuthorship W2126367595A5086592438 @default.
• W2126367595 hasAuthorship W2126367595A5089512613 @default.
• W2126367595 hasBestOaLocation W21263675951 @default.
• W2126367595 hasConcept C126322002 @default.
• W2126367595 hasConcept C143998085 @default.
• W2126367595 hasConcept C159654299 @default.
• W2126367595 hasConcept C163764329 @default.
• W2126367595 hasConcept C203014093 @default.
• W2126367595 hasConcept C2776178377 @default.
• W2126367595 hasConcept C2777658100 @default.
• W2126367595 hasConcept C2777863537 @default.
• W2126367595 hasConcept C2781228144 @default.
• W2126367595 hasConcept C2781413609 @default.
• W2126367595 hasConcept C2909179924 @default.
• W2126367595 hasConcept C502942594 @default.
• W2126367595 hasConcept C553184892 @default.

• next